What can you expect at UEGW?
Confidential. For internal use only. Not for distribution/do not share externally.
Hitting the right note: Another milestone for Entyvio
A big thank you to everyone who joined us on 10 March 2025 for the official launch of Entyvio® Academy – a brand-new suite of training modules offering comprehensive knowledge on Entyvio® and IBD.

These modules have been designed to support the onboarding and training of your Entyvio® commercial teams, whether they are new to the brand or seeking a refresher on our data and the competitive treatment landscape.

We’d like to extend our thanks to our very own ‘All stars’ team across the LOCs who have been invaluable in co-creating the Academy modules: Sofia Pimentel, Anna Wramdemark, Alessandra Caciolli, Martina Bulinová, Sarah Shaw and Alen Kurbegovic. Their insights have played a crucial role in shaping the content and design, ensuring the modules meet your teams’ training needs.

If you were unable to attend the meeting or would like to revisit it, you can watch the meeting recording here or access the meeting slides here.
Next steps... Drumroll, please!
•   Familiarise yourself with the UC Detail Aid (C-APROM/EUC/ENTY/0041) and CD Detail Aid (C-APROM/EUC/ENTY/0042)
-   Module 1: Introduction to IBD (C-APROM/INT/ENTY/0228)
-   Module 2: Entyvio® key trials and treatment (C-APROM/INT/ENTY/0229)
-   Module 3: Understanding the IBD treatment landscape
(C-APROM/INT/ENTY/0230)
•   Review the Implementation Guide (C-APROM/INT/ENTY/0263) for
guidance on how to adapt the Academy modules for local markets. Note
that the Academy modules and Implementation Guide are intended for internal use only and should not be used for promotional purposes
•   Start localising the assets for approval in your market
•   Begin planning the logistics of the launch in your market and set up training with the relevant team members to ensure a smooth rollout
Thank you for all your support in the launch and localisation of Entyvio® Academy. We’re excited to see how these modules will support and strengthen your teams’ expertise, ensuring that more patients with IBD can continue to ‘enjoy the silence’.

For the past 10 years, Takeda and Entyvio® have made significant strides in improving IBD care. We are confident that the Academy training modules will allow your commercial teams to successfully communicate and further establish Entyvio® as the preferred early advanced treatment for many more patients around the world for years to come.

If you have any questions about the Entyvio® Academy modules or how to implement these in your market, please reach out to:

Shira Megidish (Shira.Megidish@takeda.com)

Sofia Pimentel (Sofia.Pimentel@takeda.com)
#